GlassScriptPhysician profile
Matthew Potenza
NPI 1356509855
$21,602.70
in general payments reported to CMS, 2019-2025
57 companies · $3,601 in 2025
The $3,601 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,528 · 2020: $2,499 · 2021: $2,982 · 2022: $3,205 · 2023: $2,965 · 2024: $2,822 · 2025: $3,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,326 · Education: $62.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,326.09 |
| Education | $62.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,015.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,191.85 | 2019-2023 | Farxiga |
| Corcept Therapeutics | $1,772.44 | 2019-2025 | Korlym |
| Amgen INC. | $1,705.23 | 2019-2025 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,584.73 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Sanofi-Aventis U.S. LLC | $1,526.63 | 2019-2025 | |
| Lilly USA, LLC | $1,272.74 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Radius Health, INC. | $842.88 | 2019-2025 | Tymlos |
| Abbott Laboratories | $839.36 | 2019-2025 | Freestyle Libre |
| Mannkind Corporation | $824.20 | 2019-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $646.87 | 2023-2025 | Recorlev |
| Abbvie INC. | $547.51 | 2019-2025 | |
| Beta Bionics, INC. | $428.95 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amarin Pharma, INC. | $422.44 | 2019-2022 | |
| Medtronic, INC. | $365.01 | 2022-2025 | Minimed 780g |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Potenza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.